HK1255604A1 - 抗pd-l1抗體及其用途 - Google Patents

抗pd-l1抗體及其用途

Info

Publication number
HK1255604A1
HK1255604A1 HK18114733.3A HK18114733A HK1255604A1 HK 1255604 A1 HK1255604 A1 HK 1255604A1 HK 18114733 A HK18114733 A HK 18114733A HK 1255604 A1 HK1255604 A1 HK 1255604A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
Prior art date
Application number
HK18114733.3A
Other languages
English (en)
Inventor
劉禮樂
楊欣秀
羅海山
帥正蓉
劉虎
胡少平
孫曉嵐
顧紅專
段清
楊達志
Original Assignee
江蘇懷瑜藥業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江蘇懷瑜藥業有限公司 filed Critical 江蘇懷瑜藥業有限公司
Publication of HK1255604A1 publication Critical patent/HK1255604A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK18114733.3A 2016-01-04 2018-11-19 抗pd-l1抗體及其用途 HK1255604A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610003723.6A CN106939047B (zh) 2016-01-04 2016-01-04 一种pd-l1抗体及其制备方法
PCT/CN2016/112428 WO2017118321A1 (en) 2016-01-04 2016-12-27 Anti-pd-l1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HK1255604A1 true HK1255604A1 (zh) 2019-08-23

Family

ID=59273286

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114733.3A HK1255604A1 (zh) 2016-01-04 2018-11-19 抗pd-l1抗體及其用途

Country Status (6)

Country Link
US (1) US10889648B2 (zh)
EP (1) EP3400243A4 (zh)
JP (1) JP6779299B2 (zh)
CN (2) CN106939047B (zh)
HK (1) HK1255604A1 (zh)
WO (1) WO2017118321A1 (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN107298697B (zh) * 2017-08-24 2019-05-24 张灏 一种人pd-l1蛋白y123位点磷酸化抗体及其制备方法和应用
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
AU2018348430A1 (en) 2017-10-10 2020-03-12 Numab Therapeutics AG Antibodies targeting PDL1 and methods of use thereof
EP3694545A4 (en) * 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
WO2019096121A1 (en) * 2017-11-17 2019-05-23 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-l1
WO2019101196A1 (zh) * 2017-11-27 2019-05-31 山东博安生物技术有限公司 抗pd-l1的抗体及其用途
WO2019129136A1 (zh) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN115925943A (zh) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN110144010B9 (zh) 2018-02-14 2021-01-05 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途
US11976128B2 (en) 2018-03-23 2024-05-07 Board Of Regents, The University Of Texas System Human PD-L2 antibodies and methods of use therefor
US11220546B2 (en) * 2018-03-29 2022-01-11 I-Mab Biopharma Us Limited Anti-PD-L1 antibodies and uses thereof
CN113121698B (zh) * 2018-04-09 2022-11-01 原启生物科技(上海)有限责任公司 抗pd-l1抗体及其用途
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CN112512572A (zh) 2018-04-20 2021-03-16 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
BR112020023505A2 (pt) 2018-06-01 2021-03-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Composições e usos das mesmas para tratamento de doença ou condição
CN110713543B (zh) * 2018-07-11 2023-03-14 上海交通大学医学院附属仁济医院 一种抑制pd-l1棕榈酰化修饰和表达的多肽及其应用
EP3820998A4 (en) * 2018-07-11 2022-04-27 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING ANTI-PD-L1 DOMAIN CONSTRUCTS
CN109374881B (zh) * 2018-07-18 2019-07-19 益善生物技术股份有限公司 Pd-l1抗体、组合物及试剂盒
WO2020029274A1 (zh) * 2018-08-10 2020-02-13 苏州奥特铭医药科技有限公司 一种减毒棒状病毒的制备方法及应用
CN116063495A (zh) 2018-09-28 2023-05-05 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
CN111234017B (zh) * 2018-11-28 2022-09-09 优迈生物科技(连云港)有限公司 一种抗人pd-l1抗体及其抗原结合片段、制备方法和应用
CN113544146A (zh) * 2018-12-27 2021-10-22 吉加根公司 抗pd-1结合蛋白及其使用方法
EP3902563A4 (en) * 2018-12-27 2022-12-28 Gigagen, Inc. ANTI-PD-L1 BINDING PROTEINS AND METHODS OF USE THEREOF
MX2021008387A (es) * 2019-01-11 2021-10-13 Wistar Inst Anticuerpos monoclonales de and dirigidos a pd-1 para el tratamiento y prevención de cáncer.
CN110372793B (zh) * 2019-03-21 2022-09-06 南京东极医药科技有限公司 Pd-l1的纳米抗体及其临床应用
JP7302010B2 (ja) * 2019-04-11 2023-07-03 スクリップス コリア アンチボディ インスティチュート プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途
JP7212990B2 (ja) 2019-04-26 2023-01-26 アイ－エムエービー バイオファーマ ユーエス リミテッド ヒトｐｄ‐ｌ１抗体
EP3929215A4 (en) * 2019-06-10 2022-06-22 Shandong Boan Biotechnology Co., Ltd. BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF? AND ITS USE
CN110330566A (zh) * 2019-06-11 2019-10-15 南京华岩生物技术有限公司 一种具有双重可变结构域的双特异性结合的免疫球蛋白
CN110684844B (zh) * 2019-06-27 2023-01-24 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） RBPJL基因的p.P476S突变作为PD-1抗体用药指导标志物中的应用
US20220356255A1 (en) * 2019-07-15 2022-11-10 Capella Bioscience Ltd Anti-pd-l1 antibodies
US20220411513A1 (en) * 2019-09-30 2022-12-29 Harbour Biomed (Shanghai) Co., Ltd Anti-pd-l1 antigen binding protein and application thereof
CN112574314A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 一种融合蛋白及其应用
JP7450710B2 (ja) * 2019-10-21 2024-03-15 上▲海▼宏成▲薬▼▲業▼有限公司 抗ｐｄ－ｌ１抗体及びその製薬用途
CN112759647B (zh) * 2019-10-21 2024-03-26 上海宏成药业有限公司 一种抗pd-l1的抗体及其制药用途
CA3157516A1 (en) * 2019-11-08 2021-05-14 Xinyan Zhao Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
AU2021206256A1 (en) 2020-01-10 2022-07-28 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
CN113372449B (zh) * 2020-03-10 2022-09-27 中国科学院微生物研究所 一种非红细胞凝集的抗pd-l1/cd47双特异抗体及其在抗肿瘤治疗中的应用
AU2021251486A1 (en) * 2020-04-08 2022-12-08 Janssen Biotech, Inc. Anti-PHF-TAU antibodies and uses thereof
CN112684182B (zh) * 2020-12-15 2022-06-28 上海大学 一种非疾病诊断的检测pd-l1的免疫传感器系统
WO2022246154A2 (en) * 2021-05-20 2022-11-24 Dianthus Therapeutics, Inc. Antibodies that bind to c1s and uses thereof
CN116063401B (zh) * 2021-08-13 2023-12-01 中国人民解放军总医院 阻断型靶向pd-l1的超高亲和力小蛋白及用途
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
US12110344B2 (en) 2022-11-21 2024-10-08 Dianthus Therapeutics Opco, Inc. Antibodies that bind to cis and uses thereof
CN116063526A (zh) * 2022-12-31 2023-05-05 合肥天港免疫药物有限公司 抗pdl1的抗体及其用途
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838733B1 (en) 2004-12-21 2011-08-24 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
DK1907424T3 (en) * 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
MY149079A (en) * 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
WO2010054010A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CN114835812A (zh) * 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
HUE049647T2 (hu) * 2009-11-24 2020-09-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
CA2828289C (en) 2011-03-29 2020-07-21 Roche Glycart Ag Antibody fc variants
SG11201402603WA (en) * 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
KR102284247B1 (ko) * 2012-05-31 2021-08-03 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CA3139031A1 (en) * 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AU2014235453A1 (en) * 2013-03-15 2015-10-08 Genentech, Inc. Biomarkers and methods of treating PD-1 and PD-L1 related conditions
CN112546217A (zh) * 2013-09-11 2021-03-26 米迪缪尼有限公司 用于治疗肿瘤的抗b7-h1抗体
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CN105175544B (zh) * 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用

Also Published As

Publication number Publication date
CN108699146B (zh) 2021-12-03
US20190010233A1 (en) 2019-01-10
JP6779299B2 (ja) 2020-11-04
WO2017118321A1 (en) 2017-07-13
US10889648B2 (en) 2021-01-12
JP2019503687A (ja) 2019-02-14
CN108699146A (zh) 2018-10-23
EP3400243A1 (en) 2018-11-14
EP3400243A4 (en) 2019-09-25
CN106939047B (zh) 2021-08-31
CN106939047A (zh) 2017-07-11

Similar Documents

Publication Publication Date Title
HK1259426A1 (zh) Pd-l1抗體及其用途
HK1255604A1 (zh) 抗pd-l1抗體及其用途
ZA201902265B (en) Anti-pd-1 antibodies and their uses
ZA201902533B (en) Anti-pd-l1 antibodies and variants
IL273411A (en) Antibody against PD-L1 and its uses
ZA201900353B (en) Anti-pd-l1 antibodies
IL264011A (en) Antibodies against tim3 and their uses
HK1254880A1 (zh) 抗pd-1抗體及其應用
IL262092A (en) Human anti-pacap antibodies and their use
IL262295A (en) Antibodies against pd-l1
IL266738A (en) Novel antibodies and their uses
ZA202000113B (en) Anti-ctla-4 antibodies and uses thereof
IL267070A (en) Antibodies against ox40 and their uses
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
IL266049A (en) Antibodies against o1 and their uses
IL264417A (en) Anti-o2 antibodies and their uses
IL266082A (en) Anti-chikv antibodies and their use
IL258924A (en) Humanized anti-Dicoff-related protein 2 antibody and uses thereof
IL266059A (en) Anti-rankl antibodies and their uses
ZA201906513B (en) Anti-pd-l1 antibody and use thereof